Medical Technology

@xconomy.com 3 years ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 5 years ago

Censinet Takes Off With $7.8M to Track Cyber Risks in Healthcare

@xconomy.com 5 years ago

Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests

@xconomy.com 5 years ago

Six Life Science Firms Close Q3 with an IPO, More Are on the Way

@xconomy.com 5 years ago

In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect

@xconomy.com 5 years ago

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

@xconomy.com 5 years ago

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

@xconomy.com 5 years ago

Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

@xconomy.com 5 years ago

Boston Scientific Continues M&A Streak with $202M Deal for Cryterion